Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asymchem Laboratories Tianjin CoASLTY +9.40%69 Capex-to-Operating-Cash-Flow is 1.72 as of Jun. 2026, which is 91% above its 10-year median of 0.90. GuruFocus rates ASLTY with a GF Score™ of 69/100 and a GF Value™ of $5.07 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 241 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks worse than 78.42% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Asymchem Laboratories Tianjin Co Capex-to-Operating-Cash-Flow Related Terms
Asymchem Laboratories Tianjin Co Capex-to-Operating-Cash-Flow Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co Capex-to-Operating-Cash-Flow Chart
ASLTY vs VRTX, REGN, MRNA: Capex-to-Operating-Cash-Flow Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co Capex-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 1.72 mean?
Asymchem Laboratories Tianjin Co (ASLTY) has a Capex-to-Operating-Cash-Flow of 1.72 as of Jun. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Asymchem Laboratories Tianjin Co and its competitors. This is 91% above median its historical median of 0.90. Over the past decade, Asymchem Laboratories Tianjin Co's Capex-to-Operating-Cash-Flow has ranged from 0.35 to 14.67. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #189 out of 241 companies in the Biotechnology industry, placing it in the top 78.4%.
Is Asymchem Laboratories Tianjin Co's Capex-to-Operating-Cash-Flow too high?
Asymchem Laboratories Tianjin Co's current Capex-to-Operating-Cash-Flow of 1.72 is 91% above median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 14.67. The Biotechnology industry median Capex-to-Operating-Cash-Flow is 0.35. Asymchem Laboratories Tianjin Co's value of 1.72 is 391.4% above this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #189 out of 241 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's Capex-to-Operating-Cash-Flow compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #189 out of 241 companies for Capex-to-Operating-Cash-Flow. This places Asymchem Laboratories Tianjin Co in the lower half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.35. Asymchem Laboratories Tianjin Co's value of 1.72 is 391.4% above this benchmark. Historically, Asymchem Laboratories Tianjin Co's own Capex-to-Operating-Cash-Flow has ranged from 0.35 to 14.67 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 0.35, Asymchem Laboratories Tianjin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Biotechnology company?
The median Capex-to-Operating-Cash-Flow among Biotechnology companies is 0.35, based on 241 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current Capex-to-Operating-Cash-Flow of 1.72 is 391.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Asymchem Laboratories Tianjin Co and its competitors. For the Biotechnology industry, the median Capex-to-Operating-Cash-Flow is 0.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current Capex-to-Operating-Cash-Flow is 1.72, which is 91% above median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.07, compared to a current price of $8.15 — trading 60.7% above its estimated fair value. The current Capex-to-Operating-Cash-Flow is 1.72, which is 91% above median its 10-year median of 0.90 and 391.4% above the Biotechnology industry median of 0.35. Asymchem Laboratories Tianjin Co's overall GF Score™ is 69/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current Capex-to-Operating-Cash-Flow is 1.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $8.15 is trading 60.7% above its estimated GF Value™ of $5.07.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
Capex-to-Operating-Cash-Flow: 1.72 (91% above median its 10-year median of 0.90)
GF Value™: $5.07 vs. price of $8.15 (60.7% above fair value)
Industry Position: 391.4% above the Biotechnology median (#189 of 241)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
69GF Score
Get the complete analysis for ASLTY
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
